BR112022010495A2 - Método de tratamento da psoríase e outras condições auto-imunes com um inibidor prmt5 - Google Patents
Método de tratamento da psoríase e outras condições auto-imunes com um inibidor prmt5Info
- Publication number
- BR112022010495A2 BR112022010495A2 BR112022010495A BR112022010495A BR112022010495A2 BR 112022010495 A2 BR112022010495 A2 BR 112022010495A2 BR 112022010495 A BR112022010495 A BR 112022010495A BR 112022010495 A BR112022010495 A BR 112022010495A BR 112022010495 A2 BR112022010495 A2 BR 112022010495A2
- Authority
- BR
- Brazil
- Prior art keywords
- psoriasis
- autoimmune conditions
- treatment
- prmt5 inhibitor
- prmt5
- Prior art date
Links
- 229940125897 PRMT5 inhibitor Drugs 0.000 title abstract 3
- 201000004681 Psoriasis Diseases 0.000 title abstract 3
- 230000001363 autoimmune Effects 0.000 title abstract 3
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- HBGHQRGHFNTSDP-DJABAAGCSA-N (1S,2S,3S,5R)-3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl]oxy]-5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol Chemical compound CC1=NC=NC2=C1C=CN2[C@@H]1C[C@H](OC2=C3CNCCC3=C(F)C(=C2)C(F)F)[C@@H](O)[C@H]1O HBGHQRGHFNTSDP-DJABAAGCSA-N 0.000 abstract 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 abstract 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
MÉTODO DE TRATAMENTO DA PSORÍASE E OUTRAS CONDIÇÕES AUTO-IMUNES COM UM INIBIDOR PRMT5. Uso de inibidor PRMT5 tal como e incluindo (1S,2S,3S,5R)-3-((6-(difluorometil)-5-fluoro-1,2,3,4-tetra-hidroisoquinolin-8-il)óxi)-5-(4-metil-7H-pirrolo[2,3-d]pirimidin-7-il)ciclopentano-1,2-diol: , ou um sal farmaceuticamente aceitável deste, para tratar a psoríase, lúpus eritematoso sistêmico (LES), artrite reumatoide (AR), artrite psoriática e outras condições ou distúrbios auto-imunes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062957925P | 2020-01-07 | 2020-01-07 | |
| US202063116120P | 2020-11-19 | 2020-11-19 | |
| PCT/IB2021/050013 WO2021140427A1 (en) | 2020-01-07 | 2021-01-04 | Prmt5 inhibitor for use in a method of treating psoriasis and other autoimmune conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010495A2 true BR112022010495A2 (pt) | 2022-09-06 |
Family
ID=74141619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010495A BR112022010495A2 (pt) | 2020-01-07 | 2021-01-04 | Método de tratamento da psoríase e outras condições auto-imunes com um inibidor prmt5 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230025976A1 (pt) |
| EP (1) | EP4087576A1 (pt) |
| JP (1) | JP2021119129A (pt) |
| KR (1) | KR20220124225A (pt) |
| CN (1) | CN114929234A (pt) |
| AU (1) | AU2021206123A1 (pt) |
| BR (1) | BR112022010495A2 (pt) |
| CA (1) | CA3166735A1 (pt) |
| IL (1) | IL294400A (pt) |
| MX (1) | MX2022008411A (pt) |
| TW (1) | TWI823043B (pt) |
| WO (1) | WO2021140427A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| EP4188920A1 (en) | 2020-07-31 | 2023-06-07 | Tango Therapeutics, Inc. | Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| WO2018081451A1 (en) * | 2016-10-26 | 2018-05-03 | Indiana University Research And Technology Corporation | Small molecule protein arginine methyltransferase 5 (prmt5) inhibitors and methods of treatment |
| WO2019110734A1 (en) * | 2017-12-08 | 2019-06-13 | Janssen Pharmaceutica Nv | Novel spirobicyclic analogues |
| TWI732431B (zh) | 2019-01-23 | 2021-07-01 | 美商輝瑞股份有限公司 | 多形體 |
-
2021
- 2021-01-04 CN CN202180008371.2A patent/CN114929234A/zh active Pending
- 2021-01-04 TW TW110100086A patent/TWI823043B/zh active
- 2021-01-04 WO PCT/IB2021/050013 patent/WO2021140427A1/en active Application Filing
- 2021-01-04 EP EP21700082.7A patent/EP4087576A1/en not_active Withdrawn
- 2021-01-04 MX MX2022008411A patent/MX2022008411A/es unknown
- 2021-01-04 BR BR112022010495A patent/BR112022010495A2/pt not_active Application Discontinuation
- 2021-01-04 AU AU2021206123A patent/AU2021206123A1/en not_active Abandoned
- 2021-01-04 IL IL294400A patent/IL294400A/en unknown
- 2021-01-04 US US17/758,468 patent/US20230025976A1/en active Pending
- 2021-01-04 KR KR1020227026975A patent/KR20220124225A/ko unknown
- 2021-01-04 CA CA3166735A patent/CA3166735A1/en active Pending
- 2021-01-05 JP JP2021000326A patent/JP2021119129A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL294400A (en) | 2022-08-01 |
| MX2022008411A (es) | 2022-08-08 |
| CN114929234A (zh) | 2022-08-19 |
| EP4087576A1 (en) | 2022-11-16 |
| US20230025976A1 (en) | 2023-01-26 |
| CA3166735A1 (en) | 2021-07-15 |
| KR20220124225A (ko) | 2022-09-13 |
| WO2021140427A1 (en) | 2021-07-15 |
| TWI823043B (zh) | 2023-11-21 |
| AU2021206123A1 (en) | 2022-06-23 |
| JP2021119129A (ja) | 2021-08-12 |
| TW202140022A (zh) | 2021-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010495A2 (pt) | Método de tratamento da psoríase e outras condições auto-imunes com um inibidor prmt5 | |
| NO942765L (no) | Anvendelse av substituerte adenin derivater for behandling av multiple sclerose | |
| CA2059263C (en) | Composition comprising the (-) enantiomer of cis-4-amino-1-(2-hydromethyl-1,3-oxathiolan-5-yl)-(1h)-pyrimidine-2-one or an enriched composition thereof, and its uses as a pharmaceutical agent | |
| JOP20210179A1 (ar) | مثبطات إيميدازو[1، 2-b] بيريدازين IL-17A | |
| PE20211444A1 (es) | Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5 | |
| PE33495A1 (es) | Compuesto de isoxazolina util como agente antiinflamatorio | |
| NZ771886A (en) | Purinone compounds and their use in treating cancer | |
| CO5280047A1 (es) | Compuestos de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo | |
| ES2192192T3 (es) | Dieteres de catecol como inhibidores selectivos de pde iv. | |
| SI3008053T1 (en) | PHOSPHATIDYLINOSITOL 3-KINATE INHIBITORS | |
| PE20121276A1 (es) | Compuestos espirociclicos que contienen nitrogeno y su uso medicinal | |
| CL2012002937A1 (es) | Compuestos derivados de 1h-pirrolo[2,3-b]piridina o 7h-pirrolo[2,3-d]pirimidina sustituidos, moduladores de quinasa; composición farmacéutica; kit farmacéutico; método de preparación;y su uso para tratar artritis reumatoide, osteoporosis, alzheimer, cancer pancreatico, cancer de protata y mieloma multiple. | |
| MX2019007452A (es) | Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos. | |
| MX2024005335A (es) | Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos. | |
| BR112021025445A2 (pt) | Composto, composição farmacêutica, uso de um composto e método para o tratamento ou profilaxia de câncer e para o tratamento ou profilaxia de câncer de pulmão de células não pequenas | |
| US11427594B2 (en) | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers | |
| JOP20210320A1 (ar) | طرق علاج السرطان باستخدام مثبطات prmt5 | |
| HRP20210508T1 (hr) | Biciklički derivati piridina, pirazina i pirimidina kao inhibitori pi3k beta | |
| WO2021099838A9 (en) | Adenosine receptor antagonist compounds | |
| AR122357A1 (es) | Método para tratar la psoriasis y otras afecciones autoinmunitarias con un inhibidor de prmt5 | |
| MX2022005258A (es) | Derivados de benzo[b][1,4]oxazina, quinoxalina y quinolona fluoradas como inhibidores de dihidroorotato deshidrogenasa (dhodh) para el tratamiento del cancer, enfermedades autoinmunes e inflamatorias. | |
| MX2023010824A (es) | Profarmacos de compuestos de pde10. | |
| Yu et al. | Correlation study between A 3 adenosine receptor binding affinity and anti-renal interstitial fibrosis activity of truncated adenosine derivatives | |
| EA202191464A1 (ru) | ИМИДАЗО[1,2-b]ПИРИДАЗИНОВЫЕ ИНГИБИТОРЫ IL-17A | |
| Baranov | Epigraphs of A School for Fools by Sasha Sokolov as the key to understanding the structure of the novel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25G | Requested change of headquarter approved |
Owner name: PFIZER INC. (US) |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |